OncoSil Medical secures Saudi FDA approval, unlocking the Middle East’s largest healthcare market
OncoSil Medical (ASX: OSL) has received approval from the Saudi Food and Drug Authority (Saudi FDA) for its OncoSil™ device, completing the Kingdom’s regulatory process and enabling commercial access to the largest healthcare market in the Middle East.
The approval extends the device’s reach into a materially large new territory, with eligible Saudi nationals now able to access treatment with full reimbursement through the national reimbursement system. This marks an expansion for a device already approved in more than 30 countries, rather than a debut.
When big ASX news breaks, our subscribers know first
What the approval means for patients and market access
With Saudi FDA approval now in place, eligible Saudi nationals can access OncoSil™ device treatment with full reimbursement through the Kingdom’s reimbursement system. This removes out-of-pocket cost as a barrier and, according to the Company, supports broader adoption of the therapy across the country.
The reach may extend beyond domestic patients. Saudi Arabia traditionally serves as a regional referral hub for patients from across the Gulf Cooperation Council (GCC) and the wider Middle East, with patients from neighbouring countries frequently seeking specialist care within the Kingdom.
The Company noted that Saudi Arabia is supported by substantial government investment in advanced medical technologies and cancer care, a tailwind for adoption of new treatments.
The market-access opportunity rests on three pillars:
-
Reimbursement — treatment available without out-of-pocket cost for eligible Saudi nationals
-
Domestic scale — the region’s largest healthcare market
-
Regional referral — patients from across the GCC and the wider Middle East travelling to leading Saudi hospitals
Director’s perspective on the Middle East expansion
Nigel Lange, CEO & Managing Director
“Receiving Saudi FDA approval is an important step in our commercial expansion across the Middle East. Saudi Arabia represents the largest healthcare market in the region, and this approval enables eligible patients to access our technology through the national reimbursement system without personal financial burden. We also see significant potential for Saudi Arabia to serve as a regional referral hub, with patients from across the Gulf and the broader Middle East travelling to leading Saudi hospitals for advanced cancer treatment.”
OncoSil Medical acknowledged the support of its exclusive distribution partner, Abdulla Fouad Group, whose expertise the Company described as instrumental in navigating the regulatory approval process and bringing the device to the Saudi market.
Understanding the OncoSil™ device and its cancer application
The OncoSil™ device is designed to treat unresectable locally advanced pancreatic cancer (LAPC), a form of the disease that cannot be removed through surgery. It works through the selected and targeted intratumoural placement of Phosphorus-32 (³²P) microparticles, delivered alongside chemotherapy.
The clinical rationale is straightforward. The targeted approach is intended to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.
The scale of unmet clinical need underpins the commercial case for each new market. Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women globally, with approximately 500,000 new cases detected every year. Because it is generally diagnosed at a later stage, it carries a poor prognosis for long-term survival.
For investors, this high unmet need supports the commercial rationale behind each additional regulatory approval, with Saudi Arabia adding to an already broad footprint.
For investors wanting a detailed view of the clinical evidence base underpinning OncoSil’s commercial expansion, our dedicated guide to the TRIPP-FFX trial results covers how the 82.2% local disease control rate and 18.3-month median overall survival exceeded pre-specified thresholds and what the planned FOLFIRINOX label expansion submission in late 2H CY26 means for the device’s addressable patient population.
| Region / Market | Regulatory Status | Notes |
|---|---|---|
| EU & UK | CE Marking approval | Marketing authorisation across both the EU and the UK |
| US & Europe | Breakthrough Device designation | Designated in both Europe and the United States |
| Global | Approved for sale in 30+ countries | Includes EU, UK, Australia, Türkiye and Israel |
| Europe & Middle East | Commercial treatments underway | Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK |
| Saudi Arabia | New — Saudi FDA approval + reimbursement | Full reimbursement for eligible Saudi nationals |
What’s next for OncoSil Medical
The Company said it looks forward to working closely with Abdulla Fouad Group, healthcare providers and key opinion leaders throughout Saudi Arabia to commence commercial rollout and provide patients with access to its treatment.
No specific sales targets, patient volumes, or revenue figures were disclosed alongside the approval.
For investors, the Saudi entry adds a materially large, reimbursed market to an already broad approval footprint. This supports the Company’s stated commercial expansion thesis across the Middle East, with the regional referral hub dynamic offering potential reach beyond the domestic patient population.
The Saudi approval adds to a regulatory footprint that now spans more than 30 countries, and the Company’s FDA Humanitarian Device Exemption application, lodged on 3 July 2026, positions the OncoSil device for a potential first-ever entry into the United States market within approximately 45 days of submission.
Don’t Miss the Next Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.